Finishing blow therapy in lung cancer with driver gene mutation

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461172
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Nippon Medical School
• Principal Investigator: Gemma Akihiko 日本医科大学, 医学(系)研究科(研究院), 教授 (20234651)
• Co-Investigator(Kenkyū-buntansha): SEIKE Masahiro 日本医科大学, 医学部, 准教授 (30366687) ; TANAKA Nobuyuki 日本医科大学, 大学院医学研究科, 大学院教授 (80222115)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: ドライバー遺伝子 / セカンドアタック / 肺癌 / cancer stem cell / アポトーシス / 転写因子

Outline of Final Research Achievements

In order to cure lung cancer with driver gene mutation, we searched second targets of the tumors. We focused on the molecules concerning with the cancer stem cell properties in the resistant cell subpopulations after drug exposure and the molecules in p53 signaling. At first, we established five resistant subpopulations with cancer stem cell like properties of lung cancer cell lines with driver gene mutation and identified the key molecules of the resistance. In addition, we identified the transcriptional molecules in PI3K-mTOR signaling varied in the process of EGFR-TKI treatment. Drug induced apotosis was dependent on Bax- and Bak-induction pathway and activated by BH3-mimetic ABT-263.

Free Research Field

呼吸器内科